Systems biology of Alzheimer's disease: how diverse molecular changes result in memory impairment in AD
- PMID: 21333708
- DOI: 10.1016/j.neuint.2011.02.008
Systems biology of Alzheimer's disease: how diverse molecular changes result in memory impairment in AD
Abstract
Alzheimer's disease (AD) is a protein misfolding-based rapid cognitive impairment in the aging brain. Because of its very widespread molecular background, AD has been approached using genomic and proteomic methods and has accumulated a large body of data during the last 15 years. In this review, we summarize the systems biology data on AD and pay particular attention to the proteomic changes in AD. Applying a systems biology model of the synapse, we attempt to integrate protein changes and provide an explanation of why seemingly diverse molecular changes result in memory impairment. We also summarize the present state of cerebrospinal fluid (CSF) and blood biomarker studies for the diagnosis of AD as well as the results of proteomic studies in tissue cultures and animal models. Finally, we give a systems biology model of AD explaining how AD can develop in an individual manner in each particular subject but always results in a rapidly developing dementia and memory impairment.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Amyloid-beta, tau, and dementia.J Alzheimers Dis. 2009;17(4):729-36. doi: 10.3233/JAD-2009-1090. J Alzheimers Dis. 2009. PMID: 19542626 Review.
-
Deciphering the molecular basis of memory failure in Alzheimer's disease.Neuron. 2004 Sep 30;44(1):181-93. doi: 10.1016/j.neuron.2004.09.010. Neuron. 2004. PMID: 15450169 Review.
-
A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.J Ethnopharmacol. 2011 Sep 1;137(1):783-9. doi: 10.1016/j.jep.2011.06.046. Epub 2011 Jul 5. J Ethnopharmacol. 2011. PMID: 21762767
-
Age-associated memory impairment and early Alzheimer's disease. Only time will tell the difference.Arzneimittelforschung. 1995 Mar;45(3A):394-7. Arzneimittelforschung. 1995. PMID: 7763332 Clinical Trial.
-
Effect of normobaric hyperoxia on behavioral deficits and neuropathology in Alzheimer's disease mouse model.J Alzheimers Dis. 2011;27(2):317-26. doi: 10.3233/JAD-2011-110308. J Alzheimers Dis. 2011. PMID: 21799251
Cited by
-
Positive Feedback Loops in Alzheimer's Disease: The Alzheimer's Feedback Hypothesis.J Alzheimers Dis. 2018;66(1):25-36. doi: 10.3233/JAD-180583. J Alzheimers Dis. 2018. PMID: 30282364 Free PMC article. Review.
-
Toward Personalized Network Biomarkers in Alzheimer's Disease: Computing Individualized Genomic and Protein Crosstalk Maps.Front Aging Neurosci. 2017 Sep 26;9:315. doi: 10.3389/fnagi.2017.00315. eCollection 2017. Front Aging Neurosci. 2017. PMID: 29085293 Free PMC article. No abstract available.
-
Inhibition of aminoacylase 3 protects rat brain cortex neuronal cells from the toxicity of 4-hydroxy-2-nonenal mercapturate and 4-hydroxy-2-nonenal.Toxicol Appl Pharmacol. 2012 Sep 15;263(3):303-14. doi: 10.1016/j.taap.2012.07.002. Epub 2012 Jul 20. Toxicol Appl Pharmacol. 2012. PMID: 22819785 Free PMC article.
-
β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View.Molecules. 2017 Oct 10;22(10):1692. doi: 10.3390/molecules22101692. Molecules. 2017. PMID: 28994715 Free PMC article. Review.
-
Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains.J Proteome Res. 2012 Jun 1;11(6):3053-67. doi: 10.1021/pr3001546. Epub 2012 May 17. J Proteome Res. 2012. PMID: 22559202 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
